Laktimak Forte: a Modern Approach to Preventive Dysbiosis in Patients with Acute Respiratory Viral Infections
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Acute respiratory viral infections – are the most common infectious diseases affecting all age groups. WHO experts note that this most widespread human population has a steady tendency to increase in recent years. Social causes associated with the global process of everincreasing urbanization, closer contacts of people practically anywhere on the globe and the strengthening of intercontinental migration processes will contribute to the further spread of SARS. Reducing the number of complications and preventing the occurrence of the negative effects of acute respiratory viral infections are directly correlated to the treatments.
The objective: the study of the effectiveness of Laktimak Forte for patients with acute respiratory viral infections in terms of prevention of the development of dysbiosis, including and against the background of antibiotic therapy.
Materials and methods. The study includes 150 patients diagnosed with: ARI, moderate and severe, including 65 (43,3%) with complications of pneumonia. The average age of patients (Me-24.5; IQR:9,00–34,00) years. A comprehensive examination of patients during 14 days of inpatient treatment was performed: analysis of the dynamics of general blood parameters and bacteriological microflora test of feces. Statistical analysis of data and processing of results were used with the help of the package of integrated programs «SPSS Statistics 20».
Results. The dynamic observation made it possible to detect the symptoms characteristic of the gastrointestinal syndrome (GIS) (looseness to 3 times a day, abdominal pain, bloating, gurgling, gaseous eructation) in 38,4% of cases at the time of delivery. Significantly fewer patients were disturbed by nausea – only in 5,9% of cases. After treatment: in two groups complete eradication of conditionally pathogenic intestinal flora was achieved, in the third group 16 of 50 people had these pathogens (p<0.001). Complications on the part of the digestive system (development of diarrhea against the background of taking antibiotics): patients of the I group had symptoms only in 7% of cases, and people of the III group – in 87% of cases (p<0,0001). While complex therapy with Laktimak Forte, a complete normalization of intestinal microflora was observed in 92,5% of patients in the first and second groups, compared with 39,5% in the third group (p<0.001). Patients in major groups had a decrease in intoxication syndrome (Mann–Whitney’s criterion=124,50; p=0,340). The relative risk of lowering the non-specific resistance of the body of the third group patients (with standard treatment) is by 17,1 times higher (RR=17,10; 95% CI:2,76–105,70) compared with patients who received a comprehensive treatment (χ2=11,68, φ=0,578, p=0.001).
Conclusion. Patients with acute respiratory viral infections who underwent complex treatment were subject to the risk of complications, the clinical variety of symptoms and normalization of immunological parameters 14 times less compared with patients of Group III. A complete normalization of intestinal microflora was noted in 92,5% of patients in the first and second groups, compared with 39,5% of the third group.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Парфенов A.M., Ручкина И.Н., Осипов Г.А., Калоев Ю.К. Дисбактериоз кишечника: вопросы биологической терапии // Трудный пациент. – 2007. – Т. 5, № 5. – С. 23–28. Full text
Macfarlane G.T., Macfarlane S. Human colonic microbiota: Ecology, physiology, and metabolic potential of intestinal bacteria // Scand. J. Gastroenterol. – 1997. – Vol. 32, № 222. – P. 3–9. https://doi.org/10.1080/00365521.1997.11720708
Ткаченко Е.И. Лечение про- и пребиотиками – перспективный способ каузальной терапии инфекций и коррекции метаболических расстройств // Экспер. и клин. гастроэнтерол. – 2003. – № 5. – С. 177.
Thornton G., O’Sullivan М., О’’Sullivan D. et al. Human intestinal probiotic bacteria – production of antimicrobial factors // Ir. J. Med. Sci. – 1993. – Vol. 162, № 9. – P. 366–368.
Fuller R. Probiotics: Prospects of use in opportunistic infections. – N.Y., 1995. – 184 p.
Румянцев В.Т. Дисбактериоз как индикатор здоровья и показание к терапии у детей: национальный миф и научная реальность // Детская больница. – 2010. – № 1. – С. 75–77.
Ткаченко Е.И. Микробиота здорового и больного: причины изменений, пути оптимизации // Экспер. и клин. гастроэнтерол. – 2003. – № 5. – С. 176.
Гриневич В.Б., Захарченко М.М. Проблема дисбиоза кишечника в общетерапевтической практике // Экспер. и клин. гастроэнтерол. – 2003. – № 5. – С. 135.
Митрохин С.Д. Дисбактериоз: современный взгляд на проблему // Инфекции и антимикробная тер. – 2016. – № 5. – С. 15–17.
Menge Н. Erkrankungen des Magen-Darm Traktes durch Bakterien, Viren and Parasiten. Gastroenterologie-Band 2. – Munchen – Berlin – Baltimore, 2012. – S. 286.
